Real Time Touch



new TOP 200 Companies filing patents this week

new Companies with the Most Patent Filings (2010+)




Real Time Touch

Csl Behring Gmbh patents


Recent patent applications related to Csl Behring Gmbh. Csl Behring Gmbh is listed as an Agent/Assignee. Note: Csl Behring Gmbh may have other listings under different names/spellings. We're not affiliated with Csl Behring Gmbh, we're just tracking patents.

ARCHIVE: New 2018 2017 2016 2015 2014 2013 2012 2011 2010 2009 | Company Directory "C" | Csl Behring Gmbh-related inventors


Methods of treatment using alpha-1-antitrypsin compositions

A streamlined method for purifying alpha-1-antitrypsin (aat) from an aat-containing protein mixture, such as coh fraction iv precipitate, is provided. In the method of the invention, contaminating proteins are destabilized by cleavage of disulfide bonds with a reducing reagent, such as dithiol, which does not affect aat. ... Csl Behring Gmbh

Truncated von willebrand factor polypeptides for treating hemophilia

The invention relates to a polypeptide comprising a truncated von willebrand factor (vwf) for use in the treatment of a blood coagulation disorder, wherein the polypeptide carries a half-life extending moiety and is administered in molar excess over factor viii and/or endogenous vwf.. . ... Csl Behring Gmbh

Methods for preparing modified von willebrand factor

The present invention provides modified von willebrand factor molecules, methods for their preparation and uses thereof. The invention further provides pharmaceutical compositions for treating coagulation disorders.. ... Csl Behring Gmbh

Proteolytically cleavable fusion proteins with high molar specific activity

The invention relates to therapeutic fusion proteins in which a coagulation factor is fused to a half-life enhancing polypeptide, and in which both are connected by a linker peptide that is proteolytically cleavable. The cleavage of such linkers liberates the coagulation factor from activity-compromising steric hindrance caused by the half-life enhancing polypeptide and thereby allows the generation of fusion proteins may show relatively high molar specific activity when tested in coagulation-related assays. ... Csl Behring Gmbh

Modified von willebrand factor having improved half-life

The invention relates to a modified vwf molecule for use in the treatment of a blood coagulation disorder.. . ... Csl Behring Gmbh

Compounds for improving the half-life of von willebrand factor

The invention relates to a compound, preferably an antibody, capable of binding to the receptor protein clec10a for use in the treatment of a blood coagulation disorder.. . ... Csl Behring Gmbh

Pharmaceutical formulations of c1 esterase inhibitor

The present invention relates to pharmaceutical formulations comprising the c1 esterase inhibitor (“c1-inh”), exhibiting a higher stability for prolonged storage and a reduced kinematic viscosity for ameliorated use in treating or preventing disorders related to kinin formation.. . ... Csl Behring Gmbh

Sugar compositions for treating hemophilia a and/or von willebrand disease

The invention relates to compositions comprising an isolated sugar for use in the treatment of von willebrand disease and/or hemophilia a, wherein the sugar is an accessible sugar residue derived from abo(h) blood group antigen.. . ... Csl Behring Gmbh

Improved factor viii preparations suitable for therapeutic use and processes to obtain these

The present invention relates to pharmaceutical preparations comprising two-chain factor viii that are essentially free of factor viii-light chains (fviii-lcs) which are not associated with factor viii-heavy chains (fviii-hcs) having higher purity and which are less immunogenic. The invention also relates to methods to test the suitability of a pharmaceutical factor viii preparation and to methods to reduce in pharmaceutical factor viii preparations the amount of fviii-hcs which are not associated with fviii-lcs and/or of fviii-lcs which are not associated with fviii-hcs.. ... Csl Behring Gmbh

Therapy using a factor xii inhibitor in a neurotraumatic disorder

The present invention relates to the use of a direct factor xii (fxii) inhibitor in the treatment of a neurotraumatic disorder resulting from a traumatic injury of the brain (traumatic brain injury, tbi) or the spinal cord (spinal cord injury, sci).. . ... Csl Behring Gmbh

Modified coagulation factor viia with extended half-life

The present invention relates to the fields of factor vii (fvii) and factor viia (fviia) albumin linked polypeptides. More specifically, the invention relates to cdna sequences coding for human factor vii and factor viia and derivatives genetically fused to a cdna coding for human serum albumin which may be linked by oligonucleotides which code for intervening peptidic linkers such encoded derivatives exhibiting improved stability and extended functional plasma half-life, recombinant expression vectors containing such cdna sequences, host cells transformed with such recombinant expression vectors, recombinant polypeptides and derivatives which do have biological activities of the unmodified wild type protein but having improved stability and prolonged shelf-life and processes for the manufacture of such recombinant proteins and their derivatives. ... Csl Behring Gmbh

Methods of treatment using hemopexin compositions

The present invention relates generally to a method of purifying proteins. More specifically, the present inventions relates to a method of purifying haptoglobin and hemopexin from the same starting material, and uses thereof.. ... Csl Behring Gmbh

Methods of treatment using alpha-1-antitrypsin compositions

A streamlined method for purifying alpha-1-antitrypsin (aat) from an aat-containing protein mixture, such as coh fraction iv precipitate, is provided. In the method of the invention, contaminating proteins are destabilized by cleavage of disulfide bonds with a reducing reagent, such as dithiol, which does not affect aat. ... Csl Behring Gmbh

Nebulization of immunoglobulin

The invention relates to methods for generating an aerosol by nebulization of a composition comprising polyclonal immunoglobulin (ig). The selection of an efficient membrane nebulizer and a composition optimized for nebulization with such membrane nebulizer results in a particularly efficient method of generating an aerosol for administration of ig to the respiratory tract.. ... Csl Behring Gmbh

01/19/17 / #20170014509

Immunoglobulin preparation and storage system for an immunoglobulin preparation

The present invention relates to an immunoglobulin preparation comprising immunoglobulin in a mass-volume percentage of at least 4%, wherein the concentration of oxygen dissolved in the preparation at room temperature is less than 40 μmol/l.. . ... Csl Behring Gmbh








ARCHIVE: New 2018 2017 2016 2015 2014 2013 2012 2011 2010 2009



###

This listing is an abstract for educational and research purposes is only meant as a recent sample of applications filed, not a comprehensive history. Freshpatents.com is not affiliated or associated with Csl Behring Gmbh in any way and there may be associated servicemarks. This data is also published to the public by the USPTO and available for free on their website. Note that there may be alternative spellings for Csl Behring Gmbh with additional patents listed. Browse our Agent directory for other possible listings. Page by FreshPatents.com

###